Oncorus, Inc. ONCR
We take great care to ensure that the data presented and summarized in this overview for Oncorus, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ONCR
Top Purchases
Top Sells
About ONCR
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at ONCR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 30
2022
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
138,872
-5.08%
|
$0
$0.27 P/Share
|
|
Dec 29
2022
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
141,753
-4.93%
|
$0
$0.26 P/Share
|
|
Dec 28
2022
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
55,610
-1.9%
|
$0
$0.25 P/Share
|
|
Dec 27
2022
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
65,090
-2.17%
|
$0
$0.27 P/Share
|
|
Dec 22
2022
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,294
-0.28%
|
$0
$0.28 P/Share
|
|
Dec 21
2022
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
13,800
-0.46%
|
$0
$0.3 P/Share
|
|
Dec 20
2022
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
14,740
-0.49%
|
$0
$0.31 P/Share
|
|
Dec 19
2022
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
99,718
-3.18%
|
$0
$0.29 P/Share
|
|
Dec 15
2022
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,089
-0.1%
|
$0
$0.39 P/Share
|
|
Dec 14
2022
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
8,600
-0.27%
|
$0
$0.38 P/Share
|
|
Dec 13
2022
|
James E Flynn > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,097
-0.07%
|
$0
$0.41 P/Share
|
|
May 25
2022
|
Rick Wanstall CFO and Treasurer |
BUY
Open market or private purchase
|
Direct |
3,777
+6.9%
|
$3,777
$1.2 P/Share
|
|
May 20
2022
|
Rick Wanstall CFO and Treasurer |
BUY
Open market or private purchase
|
Direct |
1,610
+3.3%
|
$1,610
$1.2 P/Share
|
|
May 19
2022
|
Rick Wanstall CFO and Treasurer |
BUY
Open market or private purchase
|
Direct |
5,000
+9.88%
|
$5,000
$1.29 P/Share
|
|
May 17
2022
|
Rick Wanstall CFO and Treasurer |
BUY
Open market or private purchase
|
Direct |
1
+0.0%
|
$1
$1.2 P/Share
|
|
May 16
2022
|
Rick Wanstall CFO and Treasurer |
BUY
Open market or private purchase
|
Direct |
20,620
+33.68%
|
$20,620
$1.18 P/Share
|
|
May 13
2022
|
Rick Wanstall CFO and Treasurer |
BUY
Open market or private purchase
|
Direct |
3,898
+16.32%
|
$3,898
$1.15 P/Share
|
|
May 12
2022
|
Rick Wanstall CFO and Treasurer |
BUY
Open market or private purchase
|
Direct |
14,094
+46.69%
|
$14,094
$1.08 P/Share
|
|
Nov 19
2021
|
Theodore Ashburn President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
32,500
+24.65%
|
$32,500
$1.81 P/Share
|
|
Nov 16
2021
|
Stephen Harbin COO and Chief of Staff |
BUY
Open market or private purchase
|
Indirect |
15,000
+50.0%
|
$75,000
$5.78 P/Share
|